Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    October 2019
  1. FUKUHARA H
    Editorial Comment from Dr Fukuhara to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Oct 11. doi: 10.1111/iju.14124.
    PubMed     Text format    


  2. MATSUMOTO H
    Editorial Comment from Dr Matsumoto to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Oct 6. doi: 10.1111/iju.14131.
    PubMed     Text format    


    September 2019
  3. NOHARA T, Kato Y, Nakano T, Nakagawa T, et al
    Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14099.
    PubMed     Text format     Abstract available


  4. CHOO SH, Nishiyama H, Kitamura H, Chen CH, et al
    Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14105.
    PubMed     Text format     Abstract available


    August 2019
  5. YOSHIDA T, Kates M, Fujita K, Bivalacqua TJ, et al
    Predictive biomarkers for drug response in bladder cancer.
    Int J Urol. 2019 Aug 1. doi: 10.1111/iju.14082.
    PubMed     Text format     Abstract available


    July 2019
  6. FUJIMURA T
    Current status and future perspective of robot-assisted radical cystectomy for invasive bladder cancer.
    Int J Urol. 2019 Jul 30. doi: 10.1111/iju.14076.
    PubMed     Text format     Abstract available


  7. TEISHIMA J, Matsubara A
    Editorial Comment to Current status and future perspective of robot-assisted radical cystectomy for invasive bladder cancer.
    Int J Urol. 2019 Jul 30. doi: 10.1111/iju.14086.
    PubMed     Text format    


  8. KOJIMA T
    Editorial Comment from Dr Kojima to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, inductio
    Int J Urol. 2019 Jul 28. doi: 10.1111/iju.14074.
    PubMed     Text format    


  9. KOBAYASHI T
    Editorial Comment from Dr Kobayashi to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induc
    Int J Urol. 2019 Jul 21. doi: 10.1111/iju.14075.
    PubMed     Text format    


  10. OSAWA T, Wei JT, Abe T, Kako Y, et al
    Development of the Japanese version of the health-related quality of life questionnaire for bladder cancer patients using the Bladder Cancer Index: A pilot study.
    Int J Urol. 2019 Jul 16. doi: 10.1111/iju.14073.
    PubMed     Text format    


  11. TOIDE M, Yokoyama M, Fujiwara M, Kijima T, et al
    Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cyst
    Int J Urol. 2019 Jul 8. doi: 10.1111/iju.14054.
    PubMed     Text format    


    March 2019
  12. NAKAYAMA M, Ito Y, Hatano K, Nakai Y, et al
    Impact of sex difference on survival of bladder cancer: A population-based registry data in Japan.
    Int J Urol. 2019 Mar 27. doi: 10.1111/iju.13955.
    PubMed     Text format     Abstract available


  13. LEE A, Lee HJ, Huang HH, Ho H, et al
    Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13913.
    PubMed     Text format     Abstract available


  14. ZACHOS I
    Editorial Comment to Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13929.
    PubMed     Text format    


    February 2019
  15. YASUI M, Kawahara T, Takamoto D, Izumi K, et al
    Distribution of androgen receptor expression in the urinary bladder.
    Int J Urol. 2019;26:305-306.
    PubMed     Text format    


    January 2019
  16. KOIE T, Ohyama C, Makiyama K, Shimazui T, et al
    Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer.
    Int J Urol. 2019 Jan 28. doi: 10.1111/iju.13900.
    PubMed     Text format     Abstract available


  17. TEISHIMA J, Matsubara A
    Editorial Comment to Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer.
    Int J Urol. 2019 Jan 28. doi: 10.1111/iju.13906.
    PubMed     Text format    


  18. MIYATA Y, Matsuo T, Sakai H
    Editorial Comment from Dr Miyata et al. to Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2019 Jan 22. doi: 10.1111/iju.13893.
    PubMed     Text format     Abstract available


    December 2018
  19. HASHIMOTO T
    Editorial Comment from Dr Hashimoto to Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2018 Dec 16. doi: 10.1111/iju.13889.
    PubMed     Text format    


  20. NAKATA W, Yamamichi G, Tsujimura G, Tsujimoto Y, et al
    Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2018 Dec 2. doi: 10.1111/iju.13880.
    PubMed     Text format    


    November 2018
  21. MIYAKE M, Nakai Y, Hori S, Morizawa Y, et al
    Transient liver toxicity as a result of the oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2018 Nov 18. doi: 10.1111/iju.13856.
    PubMed     Text format    


    October 2018
  22. ADELOYE D, Harhay MO, Ayepola OO, Dos Santos JP, et al
    Estimate of the incidence of bladder cancer in Africa: A systematic review and Bayesian meta-analysis.
    Int J Urol. 2018 Oct 21. doi: 10.1111/iju.13824.
    PubMed     Text format     Abstract available


  23. MIYAKE M, Hori S, Owari T, Morizawa Y, et al
    Animal model of local tumor recurrence after resection using the murine MBT2 bladder cancer cell line in syngeneic C3H mice.
    Int J Urol. 2018 Oct 16. doi: 10.1111/iju.13834.
    PubMed     Text format    


    July 2018
  24. OHTAKA M, Kawahara T, Ishiguro Y, Sharma M, et al
    Expression of receptor activator of nuclear factor kappa B ligand in bladder cancer.
    Int J Urol. 2018 Jul 24. doi: 10.1111/iju.13756.
    PubMed     Text format    


  25. ZHANG D, Zhou C, Li Y, Gao L, et al
    Amyloid precursor protein is overexpressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors.
    Int J Urol. 2018 Jul 18. doi: 10.1111/iju.13726.
    PubMed     Text format     Abstract available


  26. NAKAI Y, Inoue K, Tsuzuki T, Shimamoto T, et al
    Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study.
    Int J Urol. 2018 Jul 12. doi: 10.1111/iju.13718.
    PubMed     Text format     Abstract available


  27. YANG J, Zhang P, Zhou H, Feng S, et al
    Prospective, randomized controlled study of the preventive effect of fosfomycin tromethamine on post-transurethral resection of bladder tumor urinary tract infection.
    Int J Urol. 2018 Jul 12. doi: 10.1111/iju.13719.
    PubMed     Text format    


    March 2018
  28. MIYAZAKI J, Onozawa M, Takaoka E, Yano I, et al
    Bacillus Calmette-Guerin strain differences as the basis for immunotherapies against bladder cancer.
    Int J Urol. 2018 Mar 5. doi: 10.1111/iju.13538.
    PubMed     Text format     Abstract available


  29. TATSUGAMI K
    Editorial Comment to Prediction models for progression of non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2018;25:218-219.
    PubMed     Text format    


    February 2018
  30. OTTO W, van Rhijn BW, Breyer J, Bertz S, et al
    Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naive stage T1 high-grade urothelial bladder cancer.
    Int J Urol. 2018 Feb 22. doi: 10.1111/iju.13532.
    PubMed     Text format     Abstract available


    December 2017
  31. FUJII Y
    Prediction models for progression of non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2017 Dec 16. doi: 10.1111/iju.13509.
    PubMed     Text format     Abstract available


  32. OHNO Y
    Editorial Comment to High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer.
    Int J Urol. 2017 Dec 7. doi: 10.1111/iju.13506.
    PubMed     Text format    


    November 2017
  33. YANG X, Shi L, Yi C, Yang Y, et al
    Astrocyte elevated gene-1 promotes invasion and epithelial-mesenchymal transition in bladder cancer cells through activation of signal transducer and activator of transcription 3.
    Int J Urol. 2017 Nov 8. doi: 10.1111/iju.13486.
    PubMed     Text format     Abstract available


  34. TAN YG, Eu EWC, Huang HH, Lau WKO, et al
    High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer.
    Int J Urol. 2017 Nov 1. doi: 10.1111/iju.13480.
    PubMed     Text format     Abstract available


    July 2017
  35. SALUJA M, Gilling P
    Intravesical bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2017 Jul 25. doi: 10.1111/iju.13410.
    PubMed     Text format     Abstract available


  36. KOBATAKE K, Hayashi T, Black PC, Goto K, et al
    Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Int J Urol. 2017 Jul 22. doi: 10.1111/iju.13389.
    PubMed     Text format     Abstract available


  37. NASELLI A
    Editorial Comment to Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Int J Urol. 2017 Jul 21. doi: 10.1111/iju.13402.
    PubMed     Text format    


    March 2017
  38. SHIMIZU F, Muto S, Taguri M, Ieda T, et al
    Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
    Int J Urol. 2017 Mar 9. doi: 10.1111/iju.13324.
    PubMed     Text format     Abstract available


    February 2017
  39. INOUE K
    5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer.
    Int J Urol. 2017;24:97-101.
    PubMed     Text format     Abstract available


    January 2017
  40. ALIMI Q, Verhoest G, Kammerer-Jacquet SF, Mathieu R, et al
    Response to Re: Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer.
    Int J Urol. 2017 Jan 13. doi: 10.1111/iju.13290.
    PubMed     Text format    


  41. MATSUMURA N, Nakamura Y, Kohjimoto Y, Nishizawa S, et al
    Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
    Int J Urol. 2017 Jan 9. doi: 10.1111/iju.13274.
    PubMed     Text format     Abstract available


    December 2016
  42. ALEVIZOPOULOS A, Tyritzis S, Leotsakos I, Anastasopoulou I, et al
    Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
    Int J Urol. 2016 Dec 22. doi: 10.1111/iju.13271.
    PubMed     Text format     Abstract available


  43. BESIROGLU H
    Re: Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer.
    Int J Urol. 2016 Dec 1. doi: 10.1111/iju.13269.
    PubMed     Text format    


    November 2016
  44. REIS LO
    Editorial Comment to Orthotopic mouse model of renal pelvic cancer using a human bladder cancer cell line.
    Int J Urol. 2016;23:963.
    PubMed     Text format    


    October 2016
  45. VIDAL A, Arnold N, Vartolomei MD, Kiss B, et al
    Oncological and functional outcomes of postoperative total parenteral nutrition after radical cystectomy in bladder cancer patients: A single-center randomized trial.
    Int J Urol. 2016 Oct 21. doi: 10.1111/iju.13228.
    PubMed     Text format     Abstract available


  46. HERMANS TJ, van de Putte EE, Horenblas S, van Rhijn BW, et al
    Extended pelvic lymph node dissection at radical cystectomy for bladder cancer improves survival: Results of a nationwide population-based study.
    Int J Urol. 2016 Oct 4. doi: 10.1111/iju.13227.
    PubMed     Text format    


    April 2016
  47. DAL MORO F, Zattoni F
    Lighting from the urethral cystoscope side: A novel technique to safely manage bowel division during intracorporeal robotic urinary diversion.
    Int J Urol. 2016;23:344-5.
    PubMed     Text format    


  48. JINZAKI M, Kikuchi E, Akita H, Sugiura H, et al
    Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma.
    Int J Urol. 2016;23:284-98.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: